226 related articles for article (PubMed ID: 8584997)
21. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
Boman KO; Jansson JH; Nyhlén KA; Nilsson TK
Thromb Haemost; 2002 Feb; 87(2):311-6. PubMed ID: 11859853
[TBL] [Abstract][Full Text] [Related]
22. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
Schved JF; Gris JC; Arnaud A; Martinez P; Sanchez N; Wautier JL; Sarlat C
J Lab Clin Med; 1992 Sep; 120(3):411-9. PubMed ID: 1517688
[TBL] [Abstract][Full Text] [Related]
23. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study.
Clausen P; Feldt-Rasmussen B; Jensen G; Jensen JS
Clin Sci (Lond); 1999 Jul; 97(1):37-43. PubMed ID: 10369792
[TBL] [Abstract][Full Text] [Related]
24. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
Stefanadi E; Tousoulis D; Antoniades C; Katsi V; Bosinakou E; Vavuranakis E; Triantafyllou G; Marinou K; Tsioufis C; Papageorgiou N; Latsios G; Stefanadis C
Int J Cardiol; 2009 Apr; 133(2):266-8. PubMed ID: 18187214
[TBL] [Abstract][Full Text] [Related]
25. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
26. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
Bellucci S; Ignatova E; Jaillet N; Boffa MC
Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
[TBL] [Abstract][Full Text] [Related]
27. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
[TBL] [Abstract][Full Text] [Related]
28. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852
[TBL] [Abstract][Full Text] [Related]
29. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.
Zareba W; Pancio G; Moss AJ; Kalaria VG; Marder VJ; Weiss HJ; Watelet LF; Sparks CE
Thromb Haemost; 2001 Sep; 86(3):791-9. PubMed ID: 11583309
[TBL] [Abstract][Full Text] [Related]
30. Patients with antiphospholipid syndrome display endothelial perturbation.
Cugno M; Borghi MO; Lonati LM; Ghiadoni L; Gerosa M; Grossi C; De Angelis V; Magnaghi G; Tincani A; Mari D; Riboldi P; Meroni PL
J Autoimmun; 2010 Mar; 34(2):105-10. PubMed ID: 19656656
[TBL] [Abstract][Full Text] [Related]
31. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
Boman K; Jansson JH; Nilsson T; Swedberg K; Cleland JG; Poole-Wilson P
Thromb Res; 2010 Feb; 125(2):e46-50. PubMed ID: 19762071
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
[TBL] [Abstract][Full Text] [Related]
33. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus.
Alizadeh Dehnavi R; Beishuizen ED; van de Ree MA; Le Cessie S; Huisman MV; Kluft C; Princen HM; Tamsma JT
Eur J Intern Med; 2008 Mar; 19(2):115-21. PubMed ID: 18249307
[TBL] [Abstract][Full Text] [Related]
34. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Martin SC; Felmeden DC; Blann AD; Beevers GD; Lip GY
Int J Cardiol; 2004 Apr; 94(2-3):293-300. PubMed ID: 15093996
[TBL] [Abstract][Full Text] [Related]
35. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Adv Med Sci; 2008; 53(1):32-6. PubMed ID: 18635422
[TBL] [Abstract][Full Text] [Related]
36. Evidence of endothelial dysfunction in patients with functionally univentricular physiology before completion of the Fontan operation.
Binotto MA; Maeda NY; Lopes AA
Cardiol Young; 2005 Feb; 15(1):26-30. PubMed ID: 15831157
[TBL] [Abstract][Full Text] [Related]
37. A preliminary study on the effects of exercising to maximum walking distance on platelet and endothelial function in patients with intermittent claudication.
Collins P; Ford I; Ball D; Macaulay E; Greaves M; Brittenden J
Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):266-73. PubMed ID: 16360327
[TBL] [Abstract][Full Text] [Related]
38. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension.
Blann AD; Tse W; Maxwell SJ; Waite MA
J Hypertens; 1994 Aug; 12(8):925-8. PubMed ID: 7529277
[TBL] [Abstract][Full Text] [Related]
39. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
40. Circulating von Willebrand factor antigen II in atherosclerosis: a comparison with von Willebrand factor and soluble thrombomodulin.
Blann AD; de Romeuf C; Mazurier C; McCollum CN
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):261-6. PubMed ID: 9663709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
